Kyverna seeks $182M IPO as biotech runs multiple autoimmune CAR-T trials

Kyverna Therapeutics aims to be the fifth biotech to IPO in 2024 as the autoimmune CAR-T cell therapy maker sets its sights on $182 million in net proceeds from a listing as “KYTX.”

If the California biotech follows through with its Nasdaq listing before Valentine’s Day, as Endpoints News Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks